The global increase in obesity and associated metabolic disorders underscores the need for effective treatments. In principle, obesity can be treated by reducing energy intake and/or increasing energy expenditure (EE). Some food ingredients have been proposed as tools for increasing EE and decreasing body fat. A prominent example is capsaicin, a pungent principle of hot pepper that activates the adreno-sympathetic nervous system and brown adipose tissue (BAT) thermogenesis, increases EE and fat oxidation, and reduces body fat (1-5). Our group recently (6) reported that a non-pungent capsaicin analog (capsinoids) increases EE through the activation of BAT in humans. Slight but significant fat-reducing effects of capsinoids are also reported in mildly obese human subjects (7-9). Significantly, the effects of capsaicin and capsinoids are much attenuated in mice lacking the transient receptor potential vanilloid 1 (TRPV1) (10), a capsaicin receptor. This suggests that the thermic and fat-reducing effects of capsaicin and capsinoids are elicited by activation of the pathway of TRPV1, the sympathetic nervous system, and BAT.
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Grains of paradise (Aframomumu melegueta [Rosco] K. Schum.) (GP), also known as Guinea pepper or Alligator pepper, belong to the Zingiberaceae family native to west Africa. GP seeds are used as a spice for food and as an agent for wide-ranging ethnobotanical uses, for example, as a remedy for treating stomachache, diarrhea, and snakebite (11) . GP seeds are very rich in nonvolatile pungent compounds such as 6-paradol, 6-gingerol, 6-shogaol and related compounds (12) (13) (14) . These compounds share an important structural feature with capsaicin, namely, a vanilloid moiety. This feature may equip them with the power to activate the pathway of TRPV1 (15, 16) , the sympathetic nervous system, and BAT, and thereby to increase EE. In fact, Iwami et al. found that the intragastric administration of an alcohol extract of GP and 6-paradol to rats enhanced the efferent discharges of sympathetic nerves to BAT and induced a significant rise in BAT temperature (17) . In a previous study by our group, a single ingestion of GP extract increased EE through the activation of BAT in men (18) . We can thus speculate that a repeated ingestion of GP extract will result in a sustained elevation of EE and a consequent reduction of body fat. In the present study we tested this hypothesis by examining the effects of a daily ingestion of GP extract on EE and body composition, particularly the subcutaneous and visceral fat content, in healthy human volunteers.
Daily Ingestion of Grains of Paradise (Aframomum melegueta)
Extract 
MATERIALS AND METHODS

Subjects.
Nineteen healthy female volunteers aged 20-22 y (20.260.2) were recruited and carefully instructed on the procedures of the study. Every subject underwent a standardized health examination. The study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures were approved by the institutional review boards of Prefectural University of Kumamoto. Written informed consent was obtained from every subject.
Test substances. GP extract was extracted from seeds of Aframomum melegueta and encapsulated as described in our previous report (18) . HPLC analysis of the extract revealed peaks respectively identified as 6-gingerol (15.2%), 6-paradol (12.5%), 6-shogaol (1.7%), and 6-gingerdione (4.0%). Other components included in the GP extract were caryophyllene and a-humulene (5%), triglyceride (20%) and palmitic and oleic acid (3%). It also contained various phenolic glycosides of which the content was not quantitated. Each capsule contained 0 mg (placebo) or 10 mg of a GP extract and 190 mg of a mixture of rapeseed oil and beeswax. The GP and placebo soft gels also contained caramel (7 mg/capsule) to equalize the color. A preliminary safety assessment confirmed that daily oral ingestion of the test capsule (4 capsules after breakfast, 3 capsules after lunch, 3 capsules after dinner) for 4 wk caused no noticeable symptoms or adverse events.
Test protocol. Each subject was given either 0 or 30 mg GP extract daily for 4 wk with a wash-out period of 2 wk according to a randomized, single-blinded crossover design. Three capsules were given orally per day, 1 capsule 30 min before each of three regular meals. Anthropometric and body composition measurements, indirect calorimetry, and blood analyses were performed before and after the 4-wk period.
Anthropometric and body composition measurements. BMI was calculated as the body weight in kilograms divided by the square of height in meters (kg/m 2 ). The percentage body fat was estimated by the multifrequency bioelectric impedance method (InBody 230 Body Composition Analyzer, Biospace, Seoul, South Korea).
The body fat distribution was determined by a computed tomography (CT) scan according to the procedure described by Tokunaga et al. (19) . The total cross-sectional area, subcutaneous fat area, and visceral fat area were measured at the level of the umbilicus. All CT scans were performed in the supine position with a HiSpeed NX/i CT scanner (General Electric Medical Systems, Milwaukee, WI). Digital Imaging and Communications in Medicine (DICOM) uncompressed images were exported to "Image J" software (National Institutes of Health, Rockville, MD) for further analyses. The intraperitoneal area with the same density as the subcutaneous fat layer was defined as the visceral fat area.
Indirect calorimetry. Whole-body EE was estimated with a respiratory gas analyzer connected to a tight-fitting breathing mask (Oxycon Delta ERICHJAEGER B.V., Bunnick, Netherlands). After fasting for 6-12 h, the subjects were asked to relax on a bed in light-clothing in a room at 22˚C, and oxygen consumption and carbon dioxide production were continuously recorded for 30 min. The stable value of the final 10-min period was used to calculate the resting EE.
Blood analyses. Blood samples were taken in the clinic after overnight fasting for measurement of the following in peripheral blood: blood properties (leucocyte count, erythrocyte count, hemoglobin, platelet count), aspartate aminotransferase, alanine aminotransferase, g-glutamyltranspeptidase, total protein, albumin, alkaline phosphatase, urea nitrogen, creatinine, blood glucose, hemoglobin A1c, total cholesterol, HDL-cholesterol, LDL-cholesterol, TAG, and free fatty acid. The blood was sampled after a 10-min rest in a sitting position. All measurements were taken by the Japanese Red Cross Kumamoto Hospital according to appropriate methods.
Data analysis. Values were expressed as means with their standard errors. A paired t-test was used to compare each group with the baseline or placebo. Correlations between initial values and changes of the abdominal fat area were assessed using Pearson's correlation coefficient. Statistics were calculated using SPSS software, version 18 (IBM, Tokyo, Japan). A p value of ,0.05 was considered statistically significant.
RESULTS
Nineteen healthy female subjects (20.260.2 y old) were recruited and given an oral dose of either GP extract or a placebo every day for 4 wk in a singleblinded, randomized, crossover study. The height, body weight, body fat content, and fat area at the level of the umbilicus were measured in every subject before and after the 4-wk period of GP or placebo ingestion. As summarized in Table 1 , there was no significant change in body weight, BMI, body fat content, or fat areas after the 4-wk treatment period. The pre-versus-post-treatment differences in the GP group were compared with those in the placebo group after the 4-wk ingestion period. As shown in Fig. 1 , the differences in body weight, BMI, body fat content, subcutaneous fat area, and total fat area were almost the same after GP and placebo inges- ). These changes in visceral fat differed significantly between the two groups (p,0.05).
The correlation between the fat area before GP ingestion and the fat area change induced by GP ingestion was examined to confirm the effects of GP on visceral fat. As shown in Fig. 2 , the GP-induced change showed a significant negative correlation with the initial visceral fat (r520.64, p50.003). In contrast, no correlation was found between the initial visceral fat and the placebo-induced change (r50.34, p50.15) . The initial subcutaneous fat was uncorrelated with the change in subcutaneous fat induced by GP (r520.007, p50.77) or placebo (r520.12, p50.62) ingestion. Whole-body EE was also measured under a resting condition before and after the 4-wk period of GP or placebo ingestion (Fig. 3) . The mean EE calculated from oxygen consumption and carbon dioxide production rose significantly from 1,402624.7 kcal/d at baseline to 1,499633.7 kcal/d after 4 wk of GP ingestion. It also rose in the placebo group, but only slightly (1,444644.0 kcal/d). Table 2 shows the effects of GP ingestion on blood parameters. Glucose and g-GTP decreased slightly and significantly after 4 wk of ingestion in both the GP and placebo groups, but all of the other parameters remained approximately unchanged, at their normal levels.
DISCUSSION
The present study demonstrated that daily ingestion of GP resulted in a significant reduction of visceral fat in humans. Earlier studies have shown that the ingestion of hot pepper, its pungent principle (capsaicin), and capsinoids (non-pungent capsaicin analogs) activate TRPV1 (1-6, 9) , the adreno-sympathetic nervous system, and BAT thermogenesis, increase EE and fat oxidation, and reduce body fat, particularly visceral fat, in both humans and small rodents. Our results and earlier results on GP extract share a common finding with the earlier results on capsaicin and capsinoids, namely, that GP is rich in 6-paradol, 6-gingerol, 6-shogaol, and other pungent compounds that have the potential to activate TRPV1 (15, 16) . Intragastric administration of either GP extract or 6-paradol enhances the efferent discharges of sympathetic nerves to BAT and significantly increases BAT temperature in rats (17) . Our group previously reported that a single ingestion of GP-extract increased EE through the activation of BAT in men (18) . Here, in the present study, we have found that a daily ingestion of GP-extract brings about a slight but significant increase in whole-body EE that may contribute, at least in part, to the fat-reducing effects of GP extract.
As the test sample is an ethanol extract of GP seeds, the compounds responsible for the observed effect of GP extract are not known at present. The GP extract contained various compounds with a vanilloid moiety such as 6-paradol, 6-gingerol and 6-shogaol (15, 16) . All these compounds are capable of activating TRPV1, which is involved in the thermic and anti-obesity effects of capsaicin and capsinoids. The thermic effect of capsaicin and capsinoids are known to be mediated through the activation of TRPV1 in the gastrointestinal tract. Therefore, the effects of GP extract may also be via gastrointestinal TRPV1, although it cannot be ruled out that some vanilloid compounds are absorbed from intestinal tract and directly activate BAT and some other energy-consuming processes. Further studies are needed to identify the compounds responsible for the thermic and fat-reducing effects of GP extract, and to clarify the action mechanism including their bioavailability. Based on the acute stimulatory effect of GP extract on BAT thermogenesis (18) , it might be rational to consider that the daily ingestion of GP extract results in a sustained increase in the thermogenic activity of BAT and thereby whole-body EE. In the present study, BAT activity could not be measured because of an ethical restriction: the activity of human BAT can be accessed by 18 F-fluorodeoxyglucose-positron emission tomography in combination with computed tomography (20) , which involves inevitable radiation exposure, and thereby its use is strictly limited, particularly for normal young females.
The fat-reducing effects of GP extract were observed only in visceral fat, not in subcutaneous or total body fat. The effects seem similar to those of capsinoid ingestion, which significantly reduces visceral fat, but not total body fat (7, 8) . The selective effects of these agents may be attributable to the different metabolic properties of visceral and subcutaneous fats. Specifically, visceral fat is more sensitive to nutritional and hormonal challenges than subcutaneous fat. We note, with interest, that the reducing effect of GP extract is negatively correlated to the initial levels of visceral fat. This implies that GP extract may have a stronger fat-reducing effect in individuals with more visceral fat. The subjects in the present study were non-obese females, so we presume they exhibited a weaker fat-reduction response than what could be expected in obese subjects.
In conclusion, daily ingestion of GP extract increases whole-body EE and decreases visceral fat in young nonobese females. Although further studies on obese subjects are needed, the present results suggest that GP extract has the potential to become an effective and safe tool for reducing body fat, mainly by preventing visceral fat accumulation.
